Business Insider22 天
Sangamo announces updated data from STAAR study
Sangamo (SGMO) announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease.
Business Wire22 天
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing ...
--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST ...